CAI NASDAQ
Credit Risk of going bust: lower than 54% of companies Debt: 4.7% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.19 (down 99.4%), Caris Life Sciences, Inc. would be worth roughly what it owes.
Total debt $452.4M against a stock market value of $9.17B.
Distance to default 5.52 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $196.7M (short-term plus half of long-term), stock volatility 68.1%; Altman Z'' -0.33. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Irving, TX 75039
US
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Denton John Russel | S-Sale | 7,500 | $31.82 | 2026-09-22 |
| Brille Brian J | S-Sale | 400,000 | $30.33 | 2026-09-17 |
| Spetzler David Baxle | S-Sale | 119,212 | $24.76 | 2026-09-04 |
| Spetzler David Baxle | S-Sale | 393,100 | $24.76 | 2026-09-03 |
| Spetzler David Baxle | S-Sale | 84,900 | $25.32 | 2026-09-03 |